Clinical trial PYTHIA IBCSG 53-14 / BIG 14-04
PYTHIA IBCSG 53-14 A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | IBCSG |
EudraCT Identifier | 2014-005387-15 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02536742 |
Inclusion criteria | ER+/HER2-. Metastatic. Endocrine resistant. Palbociclib |
Last update |